GlassScriptPhysician profile
Joel David Macy
NPI 1225031099
$6,995.23
in general payments reported to CMS, 2019-2025
39 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $521 · 2023: $1,517 · 2024: $2,490 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,460 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.89 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,009.23 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $510.11 | 2023-2025 | |
| Novo Nordisk INC | $460.80 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $458.15 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $297.09 | 2022-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $203.44 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $203.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $189.80 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.32 | 2023-2025 | Xifaxan |
| Antares Pharma, INC. | $160.33 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $156.34 | 2022-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $128.84 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Exact Sciences Corporation | $111.29 | 2024-2025 | Cologuard Collection Kit |
| Halozyme INC | $110.69 | 2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.39 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $101.60 | 2023-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.79 | 2023-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Kowa Pharmaceuticals America, INC. | $94.03 | 2023-2025 | Livalo, Zoryve, Seglentis |
| Esperion Therapeutics, INC. | $86.21 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $80.82 | 2022-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $77.73 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $76.69 | 2023-2024 | Xarelto |
| Amneal Pharmaceuticals LLC | $61.28 | 2025 | Unithroid |
| Medtronic, INC. | $57.07 | 2022-2025 | Minimed 780g, Closurefast |
| Novartis Pharmaceuticals Corporation | $50.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.13 | 2022 | |
| Aimmune Therapeutics, INC. | $40.31 | 2024 | |
| Organogenesis INC. | $39.55 | 2022 | |
| Shield Therapeutics INC | $35.36 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $32.12 | 2023 | Rexulti |
| Dexcom, INC. | $23.00 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.27 | 2025 | Gemtesa |
| Ascensia Diabetes Care US INC. | $19.03 | 2025 | |
| Currax Pharmaceuticals LLC | $17.65 | 2024 | Contrave |
| Tactile Systems Technology INC | $16.68 | 2025 | Flexitouch Plus, Nimbl |
| Radius Health, INC. | $13.93 | 2024 | Tymlos |
| Neos Therapeutics, LP | $13.10 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.02 | 2022 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Macy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.